• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

Cardiovascular Risk Reduction Tools

Article

A cardiovascular risk reference guide, Framingham global risk assessment scoring guide, cardiovascular checklist, and cardiovascular risk-reduction treatment plan.

Cardiovascular Risk Reference Guide

Patient's name________________________________________________________
Chart #______________
Date___________________
Please complete pages 1, 2, and 3 during the patient's first office visit. Place in front of the patient's chart.

CARDIOVASCULAR RISK FACTORS
Nonmodifiable

Modifiable

ORGAN DAMAGE ASSESSMENT

HYPERTENSION ASSESSMENT
Identifiable causes of hypertension or secondary hypertension (when indicated)

OTHER ASSESSMENTS

Related Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Overweight and Obesity: One Expert's 3 Wishes for the Future of Patient Care
Donna H Ryan, MD Obesity Expert Highlights 2021 Research Success and Looks to 2022 and Beyond
Related Content
Navigating the New Wave of Antiobesity Medications: What Primary Care Clinicians Should Know / Image credit: ©Antonio Diaz/AdobeStock

Navigating the New Wave of Antiobesity Medications: What Primary Care Clinicians Should Know

April 17th 2024
Article

With the rise in demand for newer antiobesity medications, clinicians may face more questions from patients. Here, a primer on the drawbacks and benefits to keep in mind.

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

August 30th 2023
Podcast

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

Breathlessness in Middle-Aged Adults Linked to Overweight/Obesity, Stress, and Respiratory Disease / Image credit: ©tassel78/AdobeStock

Breathlessness in Middle-Aged Adults Linked to Overweight/Obesity, Stress, and Respiratory Disease

April 15th 2024
Article

Results of a recent study support the importance of lifestyle interventions to reduce the burden of breathlessness in middle-aged adults.

Obesity & Type 2 Diabetes: An Expert Discussion

Obesity & Type 2 Diabetes: An Expert Discussion

June 30th 2023
Podcast

In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.

Novel Antiobesity Drug Improves Body Composition, Bone Mineral Content in Phase 2 Study / image credit escape obesity: ©Siberian Art/stock.adobe.com

Novel Antiobesity Drug Significantly Improves Body Composition, Bone Mineral Content in Phase 2 Study

April 12th 2024
Article

LPCN 2401, a combination anabolic androgen receptor agonist and α-tocopherol, decreased fat mass by 6.7% and increased lean mass by 4.4% over 36 weeks, said Lipocine, Inc.

Semaglutide 2.4 mg Improves Functional Status, Body Weight in Adults with HFpEF, Obesity, T2D / image Mikhail Kosiborod, MD St Luke's Mid America Heart institute

Semaglutide 2.4 mg Improves Functional Status, Body Weight in Adults with HFpEF, Obesity, T2D

April 8th 2024
Article

ACC.24: Results of STEP HFpEF DM showed significant improvement in quality of life measures among adults with obesity-related HFpEF and type 2 diabetes.

© 2024 MJH Life Sciences

All rights reserved.